TEVA-IMATINIB TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

IMATINIB (IMATINIB MESYLATE)

Inapatikana kutoka:

TEVA CANADA LIMITED

ATC kanuni:

L01EA01

INN (Jina la Kimataifa):

IMATINIB

Kipimo:

400MG

Dawa fomu:

TABLET

Tungo:

IMATINIB (IMATINIB MESYLATE) 400MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

30/100/500

Dawa ya aina:

Prescription

Eneo la matibabu:

ANTINEOPLASTIC AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0145503003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2013-04-02

Tabia za bidhaa

TEVA-IMATINIB (imatinib mesylate tablets)
Page 1 of 95
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVA-IMATINIB
Imatinib Mesylate Tablets
Tablets, 100 mg and 400 mg
imatinib (as imatinib mesylate), Oral
Protein kinase inhibitor
(ATC code: L01EA01)
Teva Canada Limited.
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Submission Control Number:
279590
Date of Initial Authorization:
April 02, 2013
Date of Revis_i_on:
February 28, 2024
_TEVA-IMATINIB (imatinib mesylate tablets) _
_ _
_Page 2 of 95_
RECENT MAJOR LABEL CHANGES
Section 7 Warnings and Precautions, Musculoskeletal
02/2023
Section 1 Indications
02/2024
Section 14 Clinical Trials
02/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 4
1
INDICATIONS
....................................................................................................................
4
1.1
PEDIATRICS
..................................................................................................................
5
1.2
GERIATRICS
...................................................................................................................
5
2
CONTRAINDICATIONS
...................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..................................................... 6
4
DOSAGE AND ADMINISTRATION
...............................................................................
6
4.1
DOSING CONSIDERATIONS
..............................................................................................
6
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.......................